Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 14.74 CAD 0.55%
Market Cap: 377.2m CAD
Have any thoughts about
Cipher Pharmaceuticals Inc?
Write Note

Cipher Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipher Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Cipher Pharmaceuticals Inc
TSX:CPH
Interest Income Expense
$1.5m
CAGR 3-Years
266%
CAGR 5-Years
N/A
CAGR 10-Years
14%
Bausch Health Companies Inc
TSX:BHC
Interest Income Expense
-$1.4B
CAGR 3-Years
1%
CAGR 5-Years
2%
CAGR 10-Years
-3%
Sundial Growers Inc
NASDAQ:SNDL
Interest Income Expense
-CA$6.6m
CAGR 3-Years
25%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Interest Income Expense
$80.2m
CAGR 3-Years
-2%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Interest Income Expense
$7.4m
CAGR 3-Years
245%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Interest Income Expense
-$141m
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipher Pharmaceuticals Inc
Glance View

Market Cap
377.2m CAD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPH Intrinsic Value
11.79 CAD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Cipher Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
1.5m USD

Based on the financial report for Sep 30, 2024, Cipher Pharmaceuticals Inc's Interest Income Expense amounts to 1.5m USD.

What is Cipher Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
14%

Over the last year, the Interest Income Expense growth was -14%. The average annual Interest Income Expense growth rates for Cipher Pharmaceuticals Inc have been 266% over the past three years , and 14% over the past ten years .

Back to Top